<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04870164</url>
  </required_header>
  <id_info>
    <org_study_id>MP0420-CP101</org_study_id>
    <secondary_id>2020-004365-39</secondary_id>
    <nct_id>NCT04870164</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and PK of Ensovibep (MP0420 - a New Candidate With Potential for Treatment of COVID-19)</brief_title>
  <official_title>A Phase 1, First-time-in-human, Dose Ascending Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MP0420 (a Novel Drug Candidate With Potential for Treatment of COVID-19) in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Molecular Partners AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Molecular Partners AG</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate how ensovibep is distributed throughout the body, the safety and&#xD;
      the tolerability of ensovibep in healthy volunteers&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 18, 2020</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Parallel (Part A) Sequential (Part B and Part C)</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Part A only</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Vital Signs: Blood Pressure Systolic and Diastolic (mmHg)</measure>
    <time_frame>up to day 100 (EOS)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital Signs: Heart Rate (bmp)</measure>
    <time_frame>up to day 100 (EOS)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital Signs: Tympanic Temperature (°C)</measure>
    <time_frame>up to day 100 (EOS)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital Signs: Oxygen Saturation (SpO2%)</measure>
    <time_frame>up to day 100 (EOS)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiac Safety assessed by 12-lead Electrocardiogram (ECG)</measure>
    <time_frame>up to day 100 (EOS)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical Examination</measure>
    <time_frame>up to day 100 (EOS)</time_frame>
    <description>For safety purpose, the following will be examined during full physical examinations: general appearance; head, ears, eyes, nose and throat; thyroid; lymph nodes; back and neck; heart; chest; lungs; abdomen; skin; and extremities; and the following systems will be assessed: musculoskeletal and neurological.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with Laboratory Abnormalities</measure>
    <time_frame>up to day 100 (EOS)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of local tolerability</measure>
    <time_frame>up to day 100 (EOS)</time_frame>
    <description>Number of subjects with reaction at the injection site. The injection site is assessed for any pain, tenderness, erythema and induration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with Adverse Events</measure>
    <time_frame>up to day 100 (EOS)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Observed maximum concentration (Cmax)</measure>
    <time_frame>up to day 100 (EOS)</time_frame>
    <description>The maximum observed concentration (Cmax) is estimated based on the serum concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cmax (Tmax)</measure>
    <time_frame>up to day 100 (EOS)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The area under the serum concentration-time curve (AUC)</measure>
    <time_frame>up to day 100 (EOS)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total body clearance of the drug from plasma (CL)</measure>
    <time_frame>up to day 100 (EOS)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The apparent volume of distribution during terminal phase after drug administration (Vz)</measure>
    <time_frame>up to day 100 (EOS)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Half-Life (T½)</measure>
    <time_frame>up to day 100 (EOS)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with treatment-emergent anti-drug antibodies (ADA)</measure>
    <time_frame>up to day 100 (EOS)</time_frame>
  </secondary_outcome>
  <number_of_arms>14</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>ensovibep dose 1 (infusion)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ensovibep dose 2 (infusion)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ensovibep dose 3 (infusion)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo (infusion)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ensovibep dose 4 (IV bolus)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ensovibep dose 5 (IV bolus)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ensovibep dose 6 (SC injection)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ensovibep dose 7 (SC injection)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ensovibep dose 8 (SC injection)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ensovibep dose 9 (SC injection)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ensovibep dose 10 (IM injection)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ensovibep dose 11 (IM injection)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ensovibep dose 12 (IM injection)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ensovibep dose 13 (IM injection)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ensovibep</intervention_name>
    <description>The study will start with a low-dose cohort and after a safety review escalate to the higher dose cohorts. 3 IV infusion, 2 IV bolus, 4 subcutaneous and 4 intramuscular cohorts are planned. Subjects receive one or two administration(s) on day 1, depending on the cohort.</description>
    <arm_group_label>ensovibep dose 1 (infusion)</arm_group_label>
    <arm_group_label>ensovibep dose 10 (IM injection)</arm_group_label>
    <arm_group_label>ensovibep dose 11 (IM injection)</arm_group_label>
    <arm_group_label>ensovibep dose 12 (IM injection)</arm_group_label>
    <arm_group_label>ensovibep dose 13 (IM injection)</arm_group_label>
    <arm_group_label>ensovibep dose 2 (infusion)</arm_group_label>
    <arm_group_label>ensovibep dose 3 (infusion)</arm_group_label>
    <arm_group_label>ensovibep dose 4 (IV bolus)</arm_group_label>
    <arm_group_label>ensovibep dose 5 (IV bolus)</arm_group_label>
    <arm_group_label>ensovibep dose 6 (SC injection)</arm_group_label>
    <arm_group_label>ensovibep dose 7 (SC injection)</arm_group_label>
    <arm_group_label>ensovibep dose 8 (SC injection)</arm_group_label>
    <arm_group_label>ensovibep dose 9 (SC injection)</arm_group_label>
    <other_name>MP0420</other_name>
    <other_name>DARPin</other_name>
    <other_name>COVID-19 treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One administration at day 1 by infusion.</description>
    <arm_group_label>placebo (infusion)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male or female subjects between ages of 18-65 years&#xD;
&#xD;
          -  Body mass index of 18.0-35.0 kg/m2&#xD;
&#xD;
          -  Non-smokers for at least 3 months&#xD;
&#xD;
          -  Deemed healthy on the basis of a clinical history, physical examination, ECG, vital&#xD;
             signs, and laboratory tests of blood and urine&#xD;
&#xD;
          -  Agree to follow the contraception requirements of the trial&#xD;
&#xD;
          -  Able to give fully informed written consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Positive tests for hepatitis B &amp; C, HIV&#xD;
&#xD;
          -  Severe adverse reaction to any drug&#xD;
&#xD;
          -  Drug or alcohol abuse&#xD;
&#xD;
          -  Use of over-the-counter medication (with the exception of paracetamol [acetaminophen])&#xD;
             during the 7 days before the first dose of trial medication, or prescribed medication&#xD;
             during the 28 days before first dose of trial medication&#xD;
&#xD;
          -  Any vaccination within 4 weeks before dose of trial medication&#xD;
&#xD;
          -  Participation in other clinical trials of unlicensed medicines within the previous 3&#xD;
             months&#xD;
&#xD;
          -  Loss of more than 400 mL blood within the previous 3 months&#xD;
&#xD;
          -  Vital signs outside the acceptable range&#xD;
&#xD;
          -  Clinically relevant abnormal findings at the screening assessment&#xD;
&#xD;
          -  Acute or chronic illness&#xD;
&#xD;
          -  Clinically relevant abnormal medical history or concurrent medical condition&#xD;
&#xD;
          -  Possibility that volunteer will not cooperate&#xD;
&#xD;
          -  Females who are pregnant or lactating, or who are sexually active and not using a&#xD;
             reliable method of contraception.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Medical Director MPAG</last_name>
    <phone>+41 44 755 77 00</phone>
    <email>info@molecularpartners.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>HMR</name>
      <address>
        <city>London</city>
        <zip>NW10 7EW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 28, 2021</study_first_submitted>
  <study_first_submitted_qc>April 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2021</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ensovibep</keyword>
  <keyword>COVID-19 treatment</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>Corona</keyword>
  <keyword>designed ankyrin repeat protein (DARPin®)</keyword>
  <keyword>angiotensin-converting enzyme 2 (ACE2)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

